TIL Therapies: The Impact on Cancer Research
In 2024 the FDA cleared Iovance Biotherapeutics’ TIL therapy Amtagvi (lifileucel), the first autologous, non‑CAR‑T cell treatment approved for a solid tumor—advanced melanoma. The therapy expands a patient’s own tumor‑infiltrating lymphocytes in the lab and reinfuses them, often with high‑dose IL‑2, to launch a personalized immune attack. The approval validates the commercial viability of TILs and spurs a wave of engineered candidates, such as Obsidian’s OBX‑115 and KSQ‑001EX, targeting a broader range of solid cancers. At roughly $515,000 per patient, pricing and manufacturing remain key challenges as the field eyes cold‑tumor indications.
Implantable Cytokine Factories Show Promise Against Advanced Ovarian Cancer
Researchers at Rice University and MD Anderson reported first‑in‑human results for AVB‑001, an implantable cell capsule that continuously secretes interleukin‑2 within the peritoneal cavity of patients with high‑grade serous ovarian cancer. In a Phase I dose‑escalation study of 14 platinum‑resistant...
Talphera Inc (TLPH) Q1 2026 Earnings Call Transcript
Talphera reported a $21.1 million cash balance and closed a $4.1 million financing tranche, with two additional conditional tranches of $16 million tied to study milestones. The nephro CRRT trial has surpassed the 50% enrollment target and is on track for full enrollment...
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics reported interim data from its pivotal ALPHA-3 trial, showing SemiCell achieved a 58.3% MRD clearance rate versus 16.7% in the observation arm—a 41.6% absolute improvement—alongside a near‑98% median ctDNA reduction. The safety profile was clean, with no cases...
Beyondspring Inc (BYSI) Q1 2026 Earnings Call Transcript
BeyondSpring Inc. reported that its lead asset plinabulin received FDA priority review with a PDUFA decision deadline of November 30, 2021. The company completed enrollment of 559 patients in the global Phase 3 DUBLIN‑3 trial for second‑line non‑small cell lung cancer...
Genprex Inc (GNPX) Q1 2026 Earnings Call Transcript
Genprex (GNPX) reported Papzimias generated $21.6 million in net product revenue for Q1 2026, up from $3.4 million in the prior quarter, driving total revenue to $23.3 million. The therapy now enjoys coverage for more than 90 % of insured U.S. lives and a permanent...
Humacyte Inc (HUMA) Q1 2026 Earnings Call Transcript
Humacyte reported a sharp rise in Symvess product revenue to $703,000 in Q1 2026, driven by expanding hospital approvals and its first sale to U.S. military facilities after ECAT listing. The company secured 25 Value Analysis Committee approvals covering 92...
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Transcript
PolyPid announced that its D‑PLEX100 product achieved primary and all key secondary endpoints in the SHIELD II Phase III trial, confirming a meaningful reduction in surgical site infections. The FDA provided written feedback endorsing a rolling new drug application, with...
VTv Therapeutics Inc (VTVT) Q1 2026 Earnings Call Transcript
Travere Therapeutics announced the first full FDA approval of its kidney drug Filspari for focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, expanding the product’s label beyond IgA nephropathy. In Q1 2026, Filspari net sales jumped 88% year‑over‑year to $105.2 million, driving...
Weight Loss Maintained Seven Times More Effectively with Continued Maximum Dose of Tirzepatide, Study Finds
A Phase 3b trial presented at ECO 2026 showed that continuing tirzepatide at the maximum tolerated dose (10 mg or 15 mg) after an initial 60‑week weight‑loss phase preserved a 21.9% reduction from baseline after a further 52 weeks, compared with only 9.9% in the...
Daily Pill Can Help People Maintain Weight Loss After They Come Off Jabs, Trial Shows
Scientists reported that the oral GLP‑1 receptor agonist orforglipron helps patients retain most of the weight lost with injectable tirzepatide or semaglutide. In a 12‑month randomized trial of 376 U.S. participants, those who switched to the daily pill kept about...
Personalized DNA Vaccine Doubles Glioblastoma Survival Rates
A phase‑1 trial of Geneos Therapeutics' personalized DNA vaccine GNOS‑PV01 showed it was safe and generated robust immune responses in newly diagnosed glioblastoma patients. The vaccine, which encodes up to 40 patient‑specific neoantigens, more than doubled 12‑month overall survival to...
BMS Just Signed a $15.2 Billion Drug Deal with China’s Biggest Pharma Company. The Patent Cliff Left It No Choice.
Bristol Myers Squibb (BMS) has struck a licensing deal with China’s Jiangsu Hengrui Medicine worth up to $15.2 billion for 13 early‑stage drug programmes in oncology, haematology and immunology. The agreement includes $950 million in near‑term payments and $14.25 billion tied to development,...
Slowing Parkinson’s by Blocking a Key Protein
Researchers at the University of Pennsylvania have pinpointed glycoprotein nonmetastatic melanoma B (GPNMB) as a key driver of alpha‑synuclein spread in Parkinson’s disease. In pre‑clinical models, monoclonal antibodies that block GPNMB halted the neuron‑to‑neuron transmission of toxic protein clumps. Analysis...
AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control
The United States Pharmacopeia (USP) is hosting a three-part webinar series on adeno‑associated virus (AAV) platforms, scheduled for May 19, June 16 and July 8, 2026. Each session moves from an overview of the current AAV landscape to deep dives...
Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant
A Phase I/II multicenter trial led by Washington University used CRISPR‑Cas9 to delete CD33 from donor hematopoietic stem cells in 30 high‑risk AML or MDS patients. The edited cells engrafted on schedule, with platelet recovery by day 16 and overall...
Multi-Attribute Methods Advance Analytics for Complex Therapeutic Development
At the 2026 AAPS National Biotechnology Conference, Agilent’s Dr. Ganesh Bala highlighted how multi‑attribute LC‑MS methods are reshaping analytics for complex bioconjugates such as antibody‑drug conjugates. He explained that peptide‑mapping‑based MAMs can simultaneously quantify critical quality attributes—including site‑specific conjugation and...
From Gimmick to Gold Standard
Clinical wearables have transitioned from wellness gadgets to FDA‑recognized trial endpoints, with more than 1,000 interventional studies between 2001 and 2025 already incorporating sensor data. Advances in sensor fidelity, AI‑driven analytics, and regulatory acceptance are enabling continuous cardiac, metabolic, and...
HealthcareWATCH
ICON and Advarra have formed a strategic partnership to create a connected, research‑ready site network that integrates ICON’s global trial services with Advarra’s CTMS, eISF and eSource platforms, promising faster study start‑up and reduced administrative burden. Eli Lilly reported that its...
Alkermes' Narcolepsy Phase 3 Success; Boehringer's Antibody Deal
Alkermes announced that its narcolepsy candidate Lumryz achieved its primary and key secondary endpoints in a pivotal Phase 3 trial, demonstrating statistically significant reductions in cataplexy attacks and excessive daytime sleepiness. The study enrolled 500 patients across North America and Europe...
Medisca and Dsm–Firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market
Medisca has struck a strategic partnership with dsm‑firmenich to bring a portfolio of pharmaceutical‑grade vitamin active pharmaceutical ingredients (APIs) to U.S. compounding pharmacies and 503B outsourcing facilities. The vitamins will be sourced from dsm‑firmenich’s European cGMP manufacturing sites, ensuring compliance...
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm From the University of South Carolina
20/20 BioLabs announced an exclusive worldwide licensing deal with the University of South Carolina to commercialize a patented PSA velocity algorithm that flags rapidly rising prostate‑specific antigen levels. The tool identifies aggressive prostate tumors before PSA crosses the conventional 4.0 ng/mL...
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals (NASDAQ: LXRX) announced that its management will join a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026, held at Nasdaq World Headquarters in New York. The session will be streamed live...
Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu
Rigel has signed an exclusive, global licensing agreement with Arvinas and Pfizer to develop, manufacture and commercialize the FDA‑approved oral PROTAC drug Veppanu (vepdegestrant) for ER+/HER2‑, ESR1‑mutated advanced or metastatic breast cancer. The deal includes a $70 million upfront payment, a...
EU Agrees Plan to Tackle Essential Medicine Shortages
The European Union has reached a provisional agreement on the Critical Medicines Act, a legislative package aimed at strengthening the supply chain for essential drugs. The act requires member states to diversify procurement, prioritize EU‑based manufacturing, and launch strategic projects...
STAT+: Capsida Says It Still Doesn’t Know What Caused Gene Therapy Death
Capsida Biotherapeutics announced it still cannot determine the cause of a child’s death that occurred during the September 2025 CAP-002 gene‑therapy trial, the first brain‑penetrating treatment of its kind. The investigation is stalled because the hospital conducting the study has...
Novo Says High-Dose Wegovy Can Cause 28% Weight Loss
Novo Nordisk reported that its high‑dose 7.2 mg Wegovy formulation enabled early responders to lose nearly 28 % of body weight in the 72‑week STEP UP trial. Across the 1,400‑patient study, average weight loss reached 21 %, with 27 % of participants qualifying as early...
BridgeBio’s Attruby Challenges Pfizer’s Vyndamax Legacy in Pivotal ATTR Trial
BridgeBio unveiled pivotal Phase III ATTRibute‑CM data for its FDA‑approved drug Attruby at the ESC 2026 Heart Failure congress. The study showed sustained wild‑type transthyretin levels, a 40% drop in outpatient worsening heart‑failure events, and a 34% reduction in cardiovascular hospitalisations...
Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss
Novo Nordisk presented new sub‑analyses from the STEP UP trial comparing its higher‑dose Wegovy 7.2 mg weekly injection with the approved 2.4 mg dose and placebo in over 1,400 obese adults without diabetes. Over 72 weeks, the 7.2 mg regimen produced an average 20.7%...
Contributor: Fuel Drug Development, Not Big Pharma's Profits
The author, a 65‑year‑old ALS patient, urges faster U.S. drug development for amyotrophic lateral sclerosis, highlighting the pending ACT for ALS legislation. He notes more than 200 ALS drug candidates are stalled by a system that favors large pharmaceutical firms...
US Government Studies Into Vaccine Safety Are Being Suppressed | Robert B Shpiner
The FDA withdrew two peer‑reviewed COVID‑19 vaccine safety studies—one analyzing 7.5 million Medicare beneficiaries and another covering 4.2 million recipients—after political appointees refused to sign off, despite journal acceptance. A separate Shingrix safety abstract was also blocked, even though it confirmed a...
AI-Designed Drug Reduces Fentanyl Consumption in Animal Models by Targeting Serotonin Receptors
Researchers at UC Irvine used an artificial‑intelligence platform to design a novel serotonin‑receptor drug, GATC‑1021, that dramatically lowers fentanyl self‑administration in rats. In dose‑response studies the compound cut fentanyl intake by more than 60% and maintained efficacy without developing tolerance....
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough
Daraxonrasib, a KRAS‑targeting drug, is on the brink of regulatory approval and has shown the first meaningful survival benefit for pancreatic cancer patients. The molecule binds a mutated KRAS protein long deemed “undruggable,” a breakthrough that also appears effective against...
SMC Backs First-Line Metastatic Bladder Cancer Combination After Trial Results
Scotland’s Medicines Consortium (SMC) has approved reimbursement for the first‑line combination of enfortumab vedotin and pembrolizumab for adults with unresectable or metastatic urothelial cancer. The decision follows the phase 3 EV‑302 trial, which showed median overall survival of 33.8 months versus...
Inhibrx Announces Positive Interim Results From HexAgon Trial
Inhibrx Biosciences reported positive interim Phase II data from its HexAgon trial of INBRX‑106 combined with pembrolizumab in PD‑L1‑positive metastatic head and neck squamous cell carcinoma. In the evaluable cohort, the combination achieved a 44% objective response rate versus 21% with...
EktaH Links Novel Obesity Drug to Fat Loss, Muscle Retention in Early-Phase Trial
EktaH disclosed early‑phase data for two oral candidates that activate fat‑taste receptors CD36 and GPR120, aiming to treat obesity by restoring lipid sensing. In a four‑week dose escalation study, the CD36/GPR120 agonist NKS‑5 reduced fat mass by 4.30% and modestly...
The Real Reason CGT Programs Struggle to Scale
Cell and gene therapy (CGT) programs often start with fresh leukapheresis material because it speeds early feasibility work. As patient cohorts and sites expand, the tight timing and manual handling of fresh workflows create operational variability and strain manufacturing capacity....
Roche Gets Second European Approval for Alzheimer’s Test
Roche, in partnership with Eli Lilly, secured a CE mark for its second Elecsys blood test, the pTau217 assay, enabling sales across the European Economic Area. The new test can both confirm and exclude Alzheimer’s disease, expanding on the earlier pTau181...
BMS Partners with Hengrui Pharma in a Potential ~$15.2B Deal to Advance 13 Early-Stage Programs Across Oncology, Hematology, and Immunology
Bristol‑Myers Squibb (BMS) has struck a strategic partnership with China’s Hengrui Pharma to advance 13 early‑stage programs covering oncology, hematology and immunology. Hengrui will lead early clinical development while BMS receives exclusive ex‑China rights to the assets, and Hengrui secures...
Swish Club Rebrands To SwishX, Pivots To AI For Pharma
Swish Club has rebranded as SwishX and shifted from device leasing to an agentic AI platform serving pharmaceutical and med‑tech firms. The new suite includes Tender IQ, Contract IQ, Marketing IQ and Channel IQ, aimed at automating sales, marketing, distribution...
Postbiotics Use Reduces Gingival Inflammation - Japan Study
A double‑blind, placebo‑controlled trial in Japan found that a gummy containing 500 mg of heat‑inactivated Lactiplantibacillus pentosus ONRICb0240 significantly reduced gingival inflammation over six weeks. Participants taking the postbiotic showed bleeding on probing fall from 17.6% to 12.3% and a Gingival...
RNA Therapy Slows Harmful Heart Remodeling After Heart Attack in Clinical Trial
A Phase II international trial (HF‑REVERT) tested CDR132L, an antisense inhibitor of microRNA‑132, in 294 patients who suffered a heart attack. The drug was administered in three intravenous doses alongside standard heart‑failure therapy and proved safe, with no liver, kidney or...
Is Biogen Inc. (BIIB) One of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
Biogen Inc. agreed to pay up to $850 million for exclusive Greater China rights to felzartamab, an experimental immune‑therapy from TJ Biopharma. The deal includes a $100 million upfront payment and up to $750 million in milestones and royalties. Felzartamab is in late‑stage...
Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
Regeneron Pharmaceuticals received FDA approval for Otarmeni, the first gene therapy targeting genetic hearing loss caused by OTOF gene mutations. The treatment delivers a functional copy of the OTOF gene via a viral vector directly into the cochlea and will...
AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug
AstraZeneca’s oral breast‑cancer candidate camizestrant faced a setback when an FDA advisory panel voted 6‑3 against its approval on May 1. The panel cited the SERENA‑6 trial’s inability to demonstrate a long‑term survival advantage for early switching, though it raised no...
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Immunome, Inc. filed a new drug application with the FDA for varegacestat, a gamma‑secretase inhibitor aimed at treating desmoid tumors. The filing relies on Phase 3 RINGSIDE trial data that met its primary endpoint, showing an 84% reduction in the risk...
Arvinas Inc (ARVN) Q1 2026 Earnings Call Transcript
Arvinas reported a steep revenue drop to $9.5 million in Q4, primarily due to the loss of a $40 million Novartis license, while cash fell to just over $85 million. The company cut G&A and R&D expenses, extending its cash runway into 2028,...
Animal-Testing Alternatives Will Require a Cultural Change in Research Institutions
New‑approach methodologies (NAMs) are gaining traction as alternatives to animal testing, backed by recent commitments from the US, UK and Canadian governments to fund their development and regulatory integration. While the science is advancing, the authors argue that institutional culture—routines,...
Imunon Inc (IMNN) Q1 2026 Earnings Call Transcript
Imunon reported $5.3 million cash on hand, extending its runway to mid‑Q1 2026 after a $4.5 million equity raise. Operating expenses fell 31% YoY, with R&D down 44% and CMC down 52%, cutting monthly burn to $1.25‑$1.5 million. The pivotal OVATION 3 phase III ovarian‑cancer trial...
Acurx Pharmaceuticals Inc (ACXP) Q1 2026 Earnings Call Transcript
AcelRx announced that its sufentanil product DSUVIA received Milestone C approval from the Department of Defense, allowing inclusion in U.S. Army kits. The company forecasts roughly $30 million in initial military orders over the next three years and expects broader adoption...